8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 17, 2026·SEC
Material company update
Feb 10, 2026·SEC
Monte Rosa Therapeutics, Inc.(GLUE)Earnings, Financials & Key Ratios
GLUE•NASDAQ
Price updated Jun 11, 2026
AboutMonte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.Show more
- Revenue$124M+63.5%
- EBITDA-$46M+37.2%
- Net Income-$39M+46.9%
- EPS (Diluted)-0.46+53.1%
- Gross Margin93.24%+4.5%
- EBITDA Margin-37.08%+61.6%
- Operating Margin-43.83%+59.1%
- Net Margin-31.23%+67.5%
- ROE-16.94%+53.1%
- ROIC-44.25%+49.6%
- Debt/Equity0.17-12.2%
GLUE Key Insights
Monte Rosa Therapeutics, Inc. (GLUE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 12.4% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when GLUE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GLUE Price & Volume
Monte Rosa Therapeutics, Inc. (GLUE) stock price & volume — 10-year historical chart
Loading chart...
GLUE Growth Metrics
Monte Rosa Therapeutics, Inc. (GLUE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-73.07%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-2213.02%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2757.14%
Return on Capital
10 Years-70.74%
5 Years-33.89%
3 Years-32.1%
Last Year-16.27%
GLUE Recent Earnings
Monte Rosa Therapeutics, Inc. (GLUE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 5/12 qtrs (56%)
Q2 2026Latest
May 7, 2026EPS
$0.45
Est $0.28
-60.7%
Revenue
$4M
Est $11M
-61.7%
Q2 2026
Mar 17, 2026EPS
$0.54
Est $0.35
-53.6%
Revenue
$3M
Est $16M
-82.0%
Q4 2025
Nov 6, 2025EPS
$0.33
Est $0.37
+9.9%
Revenue
$13M
Est $16M
-17.7%
Q3 2025
Aug 7, 2025EPS
$0.15
Est $0.38
+60.2%
Revenue
$23M
Est $8M
+198.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.45vs $0.28-60.7% | $4Mvs $11M-61.7% |
| Q2 2026 | Mar 17, 2026 | $0.54vs $0.35-53.6% | $3Mvs $16M-82.0% |
| Q4 2025 | Nov 6, 2025 | $0.33vs $0.37+9.9% | $13Mvs $16M-17.7% |
| Q3 2025 | Aug 7, 2025 | $0.15vs $0.38+60.2% | $23Mvs $8M+198.4% |
Based on last 12 quarters of dataView full earnings history →
GLUE Peer Comparison
Monte Rosa Therapeutics, Inc. (GLUE) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARVN | 457.46M | 7.09 | -5.54 | -0.3% | -247.54% | -44.39% | 0.02 | |
 KYMR | 6.77B | 82.96 | -22.48 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRAX | 7.16B | 247.98 | -18.40 | -100% | -43.02% | 0.00 | ||
 VRTX | 113.2B | 445.04 | 29.05 | 9.57% | 35.4% | 23.93% | 0.21 | |
 BEAM | 3.02B | 29.41 | -36.31 | 120.01% | -49.17% | -5.89% | 0.24 | |
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 PTGX | 7.06B | 109.79 | -53.56 | -89.41% | -6.48% | -17.76% | 0.02 | |
 CRL | 9.06B | 188.06 | -64.63 | -0.85% | -4.59% | -5.66% | 0.95 |
Compare GLUE vs Peers
Monte Rosa Therapeutics, Inc. (GLUE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GLUE Income Statement
Monte Rosa Therapeutics, Inc. (GLUE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 75.62M | 123.67M | 42.95M |
Revenue Growth % | - | - | - | - | - | - | 63.54% | -73.07% |
Cost of Goods Sold | 72K | 537K | 0 | 0 | 6.22M | 8.12M | 8.36M | 2.03M |
COGS % of Revenue | - | - | - | - | - | 10.74% | 6.76% | - |
Gross Profit | -72K▲ 0% | -537K▼ 645.8% | 0▲ 100.0% | 0▲ 0% | -6.22M▲ 0% | 67.5M▲ 1184.9% | 115.32M▲ 70.8% | 40.92M▲ 0% |
Gross Margin % | - | - | - | - | - | 89.26% | 93.24% | 95.28% |
Gross Profit Growth % | - | -645.83% | 100% | - | - | 1184.88% | 70.84% | - |
Operating Expenses | 7.99M | 27.47M | 72.88M | 112.38M | 137.09M | 148.61M | 169.52M | 189.2M |
OpEx % of Revenue | - | - | - | - | - | 196.52% | 137.08% | - |
Selling, General & Admin | 644K | 4M | 15.73M | 27.32M | 32.04M | 35.17M | 36.38M | 37.85M |
SG&A % of Revenue | - | - | - | - | - | 46.51% | 29.42% | - |
Research & Development | 7.35M | 23.47M | 57.16M | 85.06M | 105.05M | 121.56M | 141.5M | 153.38M |
R&D % of Revenue | - | - | - | - | - | 160.75% | 114.42% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -8.12M | -8.36M | -1000K |
Operating Income | -7.99M▲ 0% | -28.01M▼ 250.4% | -72.88M▼ 160.2% | -112.38M▼ 54.2% | -143.31M▼ 27.5% | -81.11M▲ 43.4% | -54.21M▲ 33.2% | -148.28M▲ 0% |
Operating Margin % | - | - | - | - | - | -107.26% | -43.83% | -345.21% |
Operating Income Growth % | - | -250.39% | -160.2% | -54.2% | -27.52% | 43.4% | 33.17% | - |
EBITDA | -7.92M | -27.47M | -70.75M | -108.64M | -137.09M | -72.99M | -45.85M | -139.94M |
EBITDA Margin % | - | - | - | - | - | -96.52% | -37.08% | -325.8% |
EBITDA Growth % | - | -246.79% | -157.53% | -53.55% | -26.19% | 46.76% | 37.18% | -2378.06% |
D&A (Non-Cash Add-back) | 72K | 537K | 2.13M | 3.75M | 6.22M | 8.12M | 8.36M | 8.34M |
EBIT | -7.74M | -28.01M | -72.88M | -112.38M | -143.31M | -81.11M | -54.21M | -148.28M |
Net Interest Income | -988 | 9K | 46K | 0 | 9.33M | 10.57M | 12.94M | 15.09M |
Interest Income | 12 | 9K | 46K | 3.76M | 9.33M | 10.57M | 12.94M | 15.09M |
Interest Expense | 1K | 0 | 0 | 3.76M | 0 | 0 | 0 | 0 |
Other Income/Expense | 254K | -7.87M | -1.08M | 3.88M | 8.3M | 10.98M | 14.48M | 16.4M |
Pretax Income | -7.74M▲ 0% | -35.88M▼ 363.6% | -73.96M▼ 106.1% | -108.5M▼ 46.7% | -135.01M▼ 24.4% | -70.13M▲ 48.1% | -39.72M▲ 43.4% | -131.88M▲ 0% |
Pretax Margin % | - | - | - | - | - | -92.74% | -32.12% | -307.04% |
Income Tax | 0 | 0 | 0 | 0 | 338K | 2.57M | -1.1M | -1.87M |
Effective Tax Rate % | 0% | 0% | 0% | 0% | -0.25% | -3.66% | 2.76% | 1.42% |
Net Income | -8.02M▲ 0% | -35.88M▼ 347.5% | -73.96M▼ 106.1% | -108.5M▼ 46.7% | -135.35M▼ 24.7% | -72.7M▲ 46.3% | -38.63M▲ 46.9% | -130.01M▲ 0% |
Net Margin % | - | - | - | - | - | -96.14% | -31.23% | -302.69% |
Net Income Growth % | - | -347.54% | -106.13% | -46.71% | -24.75% | 46.29% | 46.87% | -2213.02% |
Net Income (Continuing) | -7.74M | -35.88M | -73.96M | -108.5M | -135.35M | -72.7M | -38.63M | -130.01M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.18▲ 0% | -0.82▼ 355.6% | -1.59▼ 93.9% | -2.30▼ 44.7% | -2.63▼ 14.3% | -0.98▲ 62.7% | -0.46▲ 53.1% | -1.98▲ 0% |
EPS Growth % | - | -355.56% | -93.9% | -44.65% | -14.35% | 62.74% | 53.06% | -2757.14% |
EPS (Basic) | -0.18 | -0.82 | -1.59 | -2.30 | -2.63 | -0.98 | -0.46 | - |
Diluted Shares Outstanding | 44M | 44M | 46.54M | 47.23M | 51.4M | 73.91M | 83.07M | 65.54M |
Basic Shares Outstanding | 44M | 44M | 46.54M | 47.23M | 51.4M | 73.91M | 83.07M | 65.54M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
GLUE Balance Sheet
Monte Rosa Therapeutics, Inc. (GLUE) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 9.76M | 43.59M | 348.67M | 275.89M | 236.21M | 377.44M | 393.19M | 677.55M |
Cash & Short-Term Investments | 6M | 41.7M | 346.07M | 262.83M | 232.41M | 372.15M | 377.1M | 666.22M |
Cash Only | 6M | 41.7M | 346.07M | 54.91M | 128.1M | 224.25M | 129.88M | 159.86M |
Short-Term Investments | 0 | 0 | 0 | 207.91M | 104.31M | 147.9M | 247.22M | 506.36M |
Accounts Receivable | 0 | 0 | 0 | 7.66M | 505K | 173K | 4.6M | 4.61M |
Days Sales Outstanding | - | - | - | - | - | 0.83 | 13.58 | 35.15 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 3.25M | 100K | 0 | 5.4M | 3.29M | 5.12M | 11.48M | 6.72M |
Total Non-Current Assets | 1.33M | 5.79M | 17.66M | 66.5M | 67.54M | 61.29M | 55.47M | 58.88M |
Property, Plant & Equipment | 1.33M | 4.62M | 12.32M | 61.91M | 62.61M | 56.31M | 50.37M | 53.1M |
Fixed Asset Turnover | - | - | - | - | - | 1.34x | 2.46x | 0.81x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 1.16M | 5.34M | 0 | 0 | 0 | 0 | 4.95M |
Other Non-Current Assets | 0 | 0 | 0 | 4.6M | 4.93M | 4.98M | 5.1M | 5.78M |
Total Assets | 11.09M▲ 0% | 49.38M▲ 345.1% | 366.33M▲ 641.9% | 342.39M▼ 6.5% | 303.75M▼ 11.3% | 438.73M▲ 44.4% | 448.66M▲ 2.3% | 736.43M▲ 0% |
Asset Turnover | - | - | - | - | - | 0.17x | 0.28x | 0.09x |
Asset Growth % | - | 345.09% | 641.89% | -6.54% | -11.28% | 44.44% | 2.26% | 139.99% |
Total Current Liabilities | 4.29M | 29.27M | 16.64M | 25.57M | 46.59M | 156.95M | 64.21M | 71.04M |
Accounts Payable | 3.19M | 7.07M | 6.56M | 7.86M | 11.15M | 17.21M | 3.55M | 7.9M |
Days Payables Outstanding | 16.2K | 4.8K | - | - | 654.21 | 773.73 | 155.07 | 1.42K |
Short-Term Debt | 750K | 0 | 0 | 0 | 0 | 0 | 4.4M | 4.48M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 17.68M | 117.23M | 29.57M | 105.83M |
Other Current Liabilities | 0 | 21.08M | 840K | 10.64M | 9.26M | 11.57M | 26.69M | 25.59M |
Current Ratio | 2.27x | 1.49x | 20.96x | 10.79x | 5.07x | 2.40x | 6.12x | 9.54x |
Quick Ratio | 2.27x | 1.49x | 20.96x | 10.79x | 5.07x | 2.40x | 6.12x | 9.54x |
Cash Conversion Cycle | - | - | - | - | - | - | - | -1.38K |
Total Non-Current Liabilities | 18.95M | 68.83M | 2.18M | 45.41M | 77.91M | 58.85M | 151.39M | 143.48M |
Long-Term Debt | 0 | 67.76M | 0 | 0 | 0 | 0 | 34.79M | 34.58M |
Capital Lease Obligations | 0 | 0 | 0 | 43.87M | 42.88M | 39M | 0 | 37.04M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 18.95M | 0 | 2.18M | 1.53M | 2.71M | 3.7M | 5.26M | 108.89M |
Total Liabilities | 23.24M | 98.11M | 18.81M | 70.98M | 124.5M | 215.8M | 215.6M | 214.51M |
Total Debt | 750K | 67.76M | 0 | 47M | 46.04M | 42.72M | 39.19M | 39.06M |
Net Debt | -5.25M | 26.07M | -346.07M | -7.91M | -82.06M | -181.54M | -90.69M | -120.8M |
Debt / Equity | - | - | - | 0.17x | 0.26x | 0.19x | 0.17x | 0.07x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.28x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.86x |
Interest Coverage | -7739.00x | - | - | -29.86x | - | - | - | - |
Total Equity | -12.15M▲ 0% | -48.73M▼ 301.1% | 347.51M▲ 813.2% | 271.41M▼ 21.9% | 179.25M▼ 34.0% | 222.94M▲ 24.4% | 233.06M▲ 4.5% | 521.92M▲ 0% |
Equity Growth % | - | -301.12% | 813.17% | -21.9% | -33.96% | 24.37% | 4.54% | 133.19% |
Book Value per Share | -0.28 | -1.11 | 7.47 | 5.75 | 3.49 | 3.02 | 2.81 | 7.96 |
Total Shareholders' Equity | -12.15M | -48.73M | 347.51M | 271.41M | 179.25M | 222.94M | 233.06M | 521.92M |
Common Stock | 50K | 1K | 5K | 5K | 5K | 6K | 7K | 8K |
Retained Earnings | -12.2M | -48.08M | -122.03M | -230.54M | -365.89M | -438.59M | -477.21M | -521.72M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -1.06M | -2.02M | -1.75M | -2.72M | -3.36M | -3.83M | -4.75M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GLUE Cash Flow Statement
Monte Rosa Therapeutics, Inc. (GLUE) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -6.17M | -23.05M | -59.36M | -92.47M | -43.8M | 42M | -22.8M | -14.68M |
Operating CF Margin % | - | - | - | - | - | 55.53% | -18.43% | - |
Operating CF Growth % | - | -273.45% | -157.51% | -55.76% | 52.63% | 195.88% | -154.29% | 437.82% |
Net Income | -7.74M | -35.88M | -73.96M | -108.5M | -135.35M | -72.7M | -38.63M | -130.01M |
Depreciation & Amortization | 72K | 537K | 2.13M | 3.75M | 6.22M | 8.12M | 8.36M | 8.97M |
Stock-Based Compensation | 0 | 354K | 5.2M | 11.66M | 16.67M | 18.13M | 18.86M | 13.57M |
Deferred Taxes | 0 | 0 | 17K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -276K | 7.68M | 960K | 2.76M | -3.81M | -2.95M | -2.2M | 122.31M |
Working Capital Changes | 1.77M | 4.25M | 6.29M | -2.13M | 72.47M | 91.4M | -9.19M | -29.51M |
Change in Receivables | 0 | 0 | 0 | -187 | 1.9M | 332K | -7M | -970K |
Change in Inventory | 0 | 0 | 0 | 187 | 0 | 0 | 0 | 0 |
Change in Payables | 2.86M | 3.44M | -706K | -744K | 5.76M | 6.25M | -13.71M | -7.34M |
Cash from Investing | -1.39M | -3.39M | -9.65M | -219.22M | 88.8M | -44.45M | -101.83M | -262.6M |
Capital Expenditures | -1.39M | -3.39M | -9.73M | -12.91M | -19.04M | -3.99M | -4.7M | -4.98M |
CapEx % of Revenue | - | - | - | - | - | 5.27% | 3.8% | 11.6% |
Acquisitions | 0 | 0 | 79K | 109K | 62K | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 38.79M |
Cash from Financing | 15M | 60.06M | 377.56M | 20.47M | 27.49M | 98.89M | 30.35M | 358.67M |
Debt Issued (Net) | 750K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 14.25M | 60.06M | 380.75M | 20.05M | 27.49M | 303K | 30.35M | 358.32M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -641K | 0 | 0 |
Other Financing | 0 | 0 | -3.19M | 411K | 0 | 98.59M | 0 | 348K |
Net Change in Cash | 7.44M▲ 0% | 32.45M▲ 336.1% | 308.55M▲ 850.7% | -291.22M▼ 194.4% | 72.49M▲ 124.9% | 96.44M▲ 33.0% | -94.28M▼ 197.8% | 81.4M▲ 0% |
Free Cash Flow | -7.56M▲ 0% | -26.44M▼ 249.9% | -69.09M▼ 161.3% | -105.38M▼ 52.5% | -62.84M▲ 40.4% | 38.01M▲ 160.5% | -27.5M▼ 172.3% | -19.66M▲ 0% |
FCF Margin % | - | - | - | - | - | 50.26% | -22.23% | -45.76% |
FCF Growth % | - | -249.85% | -161.31% | -52.51% | 40.36% | 160.48% | -172.35% | -164.49% |
FCF per Share | -0.17 | -0.60 | -1.48 | -2.23 | -1.22 | 0.51 | -0.33 | -0.30 |
FCF Conversion (FCF/Net Income) | 0.77x | 0.64x | 0.80x | 0.85x | 0.32x | -0.58x | 0.59x | 0.15x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GLUE Key Ratios
Monte Rosa Therapeutics, Inc. (GLUE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -49.51% | -35.06% | -60.07% | -36.15% | -16.94% | -40.99% |
| Return on Invested Capital (ROIC) | - | - | -63.63% | -59.6% | -87.79% | -44.25% | -51.67% |
| Gross Margin | - | - | - | - | 89.26% | 93.24% | 95.28% |
| Net Margin | - | - | - | - | -96.14% | -31.23% | -302.69% |
| Debt / Equity | - | - | 0.17x | 0.26x | 0.19x | 0.17x | 0.07x |
| Interest Coverage | - | - | -29.86x | - | - | - | - |
| FCF Conversion | 0.64x | 0.80x | 0.85x | 0.32x | -0.58x | 0.59x | 0.15x |
| Revenue Growth | - | - | - | - | - | 63.54% | -73.07% |
Related:GLUE Dividend History·GLUE Revenue History·GLUE Price History·GLUE P/E History·GLUE Financial Ratios·GLUE Institutional Holders
GLUE SEC Filings & Documents
Monte Rosa Therapeutics, Inc. (GLUE) SEC filings — annual & quarterly reports (10-K, 10-Q)
GLUE Frequently Asked Questions
Monte Rosa Therapeutics, Inc. (GLUE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Monte Rosa Therapeutics, Inc. (GLUE) reported $43.0M in revenue for fiscal year 2025.
Monte Rosa Therapeutics, Inc. (GLUE) grew revenue by 63.5% over the past year. This is strong growth.
Monte Rosa Therapeutics, Inc. (GLUE) reported a net loss of $130.0M for fiscal year 2025.
Dividend & Returns
Monte Rosa Therapeutics, Inc. (GLUE) has a return on equity (ROE) of -16.9%. Negative ROE indicates the company is unprofitable.
Monte Rosa Therapeutics, Inc. (GLUE) had negative free cash flow of $19.7M in fiscal year 2025, likely due to heavy capital investments.